Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma
Modulation of commensal gut microbiota is increasingly recognized as a promising strategy to reduce mortality in patients with malignant diseases, but monitoring for dysbiosis is generally not routine clinical practice due to equipment, expertise and funding required for sequencing analysis. A low-t...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2081475 |
| _version_ | 1811254407178747904 |
|---|---|
| author | Maren Schmiester René Maier René Riedel Pawel Durek Marco Frentsch Stefan Kolling Mir-Farzin Mashreghi Robert Jenq Liangliang Zhang Christine B. Peterson Lars Bullinger Hyun-Dong Chang Il-Kang Na |
| author_facet | Maren Schmiester René Maier René Riedel Pawel Durek Marco Frentsch Stefan Kolling Mir-Farzin Mashreghi Robert Jenq Liangliang Zhang Christine B. Peterson Lars Bullinger Hyun-Dong Chang Il-Kang Na |
| author_sort | Maren Schmiester |
| collection | DOAJ |
| description | Modulation of commensal gut microbiota is increasingly recognized as a promising strategy to reduce mortality in patients with malignant diseases, but monitoring for dysbiosis is generally not routine clinical practice due to equipment, expertise and funding required for sequencing analysis. A low-threshold alternative is microbial diversity profiling by single-cell flow cytometry (FCM), which we compared to 16S rRNA sequencing in human fecal samples and employed to characterize longitudinal changes in the microbiome composition of patients with aggressive B-cell non-Hodgkin lymphoma undergoing chemoimmunotherapy. Diversity measures obtained from both methods were correlated and captured identical trends in microbial community structures, finding no difference in patients’ pretreatment alpha or beta diversity compared to healthy controls and a significant and progressive loss of alpha diversity during chemoimmunotherapy. Our results highlight the potential of FCM-based microbiome profiling as a reliable and accessible diagnostic tool that can provide novel insights into cancer therapy-associated dysbiosis dynamics. |
| first_indexed | 2024-04-12T17:06:58Z |
| format | Article |
| id | doaj.art-131978702d9042d08878dcd1673b4c7e |
| institution | Directory Open Access Journal |
| issn | 1949-0976 1949-0984 |
| language | English |
| last_indexed | 2024-04-12T17:06:58Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj.art-131978702d9042d08878dcd1673b4c7e2022-12-22T03:23:55ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2081475Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphomaMaren Schmiester0René Maier1René Riedel2Pawel Durek3Marco Frentsch4Stefan Kolling5Mir-Farzin Mashreghi6Robert Jenq7Liangliang Zhang8Christine B. Peterson9Lars Bullinger10Hyun-Dong Chang11Il-Kang Na12Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyDeutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, GermanyDeutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, GermanyDeutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, GermanyBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, GermanyBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, GermanyBIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, GermanyDepartment of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USADepartment of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX, USADepartment of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyDeutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institute of the Leibniz Association, Berlin, GermanyDepartment of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyModulation of commensal gut microbiota is increasingly recognized as a promising strategy to reduce mortality in patients with malignant diseases, but monitoring for dysbiosis is generally not routine clinical practice due to equipment, expertise and funding required for sequencing analysis. A low-threshold alternative is microbial diversity profiling by single-cell flow cytometry (FCM), which we compared to 16S rRNA sequencing in human fecal samples and employed to characterize longitudinal changes in the microbiome composition of patients with aggressive B-cell non-Hodgkin lymphoma undergoing chemoimmunotherapy. Diversity measures obtained from both methods were correlated and captured identical trends in microbial community structures, finding no difference in patients’ pretreatment alpha or beta diversity compared to healthy controls and a significant and progressive loss of alpha diversity during chemoimmunotherapy. Our results highlight the potential of FCM-based microbiome profiling as a reliable and accessible diagnostic tool that can provide novel insights into cancer therapy-associated dysbiosis dynamics.https://www.tandfonline.com/doi/10.1080/19490976.2022.2081475Flow cytmetrymicrobiomeB-cell non-Hodgkin lymphomalongitudinaldysbiosis |
| spellingShingle | Maren Schmiester René Maier René Riedel Pawel Durek Marco Frentsch Stefan Kolling Mir-Farzin Mashreghi Robert Jenq Liangliang Zhang Christine B. Peterson Lars Bullinger Hyun-Dong Chang Il-Kang Na Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma Gut Microbes Flow cytmetry microbiome B-cell non-Hodgkin lymphoma longitudinal dysbiosis |
| title | Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma |
| title_full | Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma |
| title_fullStr | Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma |
| title_full_unstemmed | Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma |
| title_short | Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma |
| title_sort | flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive b cell non hodgkin lymphoma |
| topic | Flow cytmetry microbiome B-cell non-Hodgkin lymphoma longitudinal dysbiosis |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2081475 |
| work_keys_str_mv | AT marenschmiester flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT renemaier flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT reneriedel flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT paweldurek flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT marcofrentsch flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT stefankolling flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT mirfarzinmashreghi flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT robertjenq flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT liangliangzhang flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT christinebpeterson flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT larsbullinger flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT hyundongchang flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma AT ilkangna flowcytometrycanreliablycapturegutmicrobialcompositioninhealthyadultsaswellasdysbiosisdynamicsinpatientswithaggressivebcellnonhodgkinlymphoma |